EAM
NTLA icon

Eventide Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Eventide Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-551,400
Closed -$30.3M – 173
2020
Q4 		$30.3M Buy
+551,400
New +$20M 0.47% 69

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eventide Asset Management's NTLA Position: Q1 2024 in Review

Eventide Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 372,665 shares — an estimated $11.4M sold.

Eventide Asset Management first reported a position in NTLA in Q3 2022 and held it in 6 quarters. The position peaked at $20.1M in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Eventide Asset Management reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Eventide Asset Management sold 372,665 Intellia Therapeutics shares in Q1 2024, an estimated $11.4M.
  • Eventide Asset Management first reported a position in Intellia Therapeutics in Q3 2022 and held it in 6 quarters.
  • Eventide Asset Management's Intellia Therapeutics position peaked at $20.1M in Q2 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Eventide Asset Management's 13F filing for Q1 2024, filed 15 May 2024.